| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036697 |
| Receipt No. | R000041814 |
| Scientific Title | A screening study of HER2 expression for biliary tract cancer |
| Date of disclosure of the study information | 2019/05/09 |
| Last modified on | 2022/11/13 (Ver. 4) |
| Basic information | ||
| Public title | A screening study of HER2 expression for biliary tract cancer | |
| Acronym | HERB preSCR | |
| Scientific Title | A screening study of HER2 expression for biliary tract cancer | |
| Scientific Title:Acronym | HERB preSCR | |
| Region |
|
|
| Condition | |||
| Condition | biliary tract cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To detect HER2 expressing biliary tract cancer using HER2 testing |
| Basic objectives2 | Others |
| Basic objectives -Others | Screening study |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | HER2 expression |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Histologically proven adenocarcinoma or adenosquamous carcinoma
2. Unresectable or recurrent biliary tract cancer by chest computed tomography (CT) and enhanced abdominal/pelvic CT or magnetic resonance imaging (MRI). 3. Age, 20 years or elder. 4. Written informed consent. |
|||
| Key exclusion criteria | None | |||
| Target sample size | 200 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Cancer Center Hospital | ||||||
| Division name | Department of Hepatobiliary and Pancreatic Oncology | ||||||
| Zip code | 104-0045 | ||||||
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan | ||||||
| TEL | 03-3542-2511 | ||||||
| cmorizan@ncc.go.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Cancer Center Hospital | ||||||
| Division name | Department of Hepatobiliary and Pancreatic Oncology | ||||||
| Zip code | 104-0045 | ||||||
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan | ||||||
| TEL | 03-3542-2511 | ||||||
| Homepage URL | |||||||
| aohba@ncc.go.jp | |||||||
| Sponsor | |
| Institute | National Cancer Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Agency for Medical Research and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | NCC IRB |
| Address | 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan |
| Tel | 03-3542-2511 |
| irst@ncc.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 300 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | To detect HER2 expressing biliary tract cancer using HER2 testing. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000041814 |